Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Hiroyoshi Koide"'
Autor:
Hidetoshi Sumimoto, Satoshi Noda, Hiroyoshi Koide, Yutaro Douke, Kosuke Sakai, Akihito Nishikawa, Azumi Tomioka, Maki Hori, Hiromi Nakato, Yuri Kimura, Aya Tokuda, Atsushi Takano, Koji Teramoto, Satoshi Murata, Yataro Daigo
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0306995 (2024)
Immune checkpoint inhibitors (ICIs) have been widely used as standard therapies for various cancers. However, in 20-30% of cases, ICIs can lead to immune-related adverse events (irAEs), which sometimes require discontinuation of treatment. Due to the
Externí odkaz:
https://doaj.org/article/bc0fbd3f6a2940db8789afc28ca8bcbb
Autor:
Sayaka Suzuki-Ajihara, Megumi Saito-Tsuruoka, Hiroko Harashima, Katsumi Arai, Hiroyoshi Koide, Yukiko Yatsuka, Atsuko Imai-Okazaki, Yasushi Okazaki, Kei Murayama, Chikahiko Numakura, Yuko Akioka, Akira Ohtake
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 35, Iss , Pp 100966- (2023)
The identification of the m.12207G > A variant in MT-TS2, (NC_012920.1:m.12207G > A) was first reported in 2006. The affected individual presented with developmental delay, feeding difficulty, proximal muscle weakness, and lesions within her basal ga
Externí odkaz:
https://doaj.org/article/20f6712ad8bf48159c020c1d77d87904
Autor:
Daiki Hira, Hiroyoshi Koide, Shigemi Nakamura, Toyoko Okada, Kazunori Ishizeki, Masafumi Yamaguchi, Setsuko Koshiyama, Tetsuya Oguma, Kayoko Ito, Saori Funayama, Yuko Komase, Shin-Ya Morita, Kohshi Nishiguchi, Yasutaka Nakano, Tomohiro Terada
Publikováno v:
PLoS ONE, Vol 13, Iss 2, p e0193082 (2018)
The patients' inhalation flow pattern is one of the significant determinants for clinical performance of inhalation therapy. However, the development of inhalation flow meters for various inhalation devices has been unable to keep up with the increas
Externí odkaz:
https://doaj.org/article/b950aecea15446d7b939b38572e68b8d
Autor:
Hiroyoshi, Koide, Satoshi, Noda, Yumi, Okunuki, Shigehiro, Owaki, Takeshi, Shimizu, Tomohiro, Terada, Shin-Ya, Morita
Publikováno v:
In Vivo
Background/Aim:Concurrent chemoradiotherapy with high-dose cisplatin (CDDP-RT) is the standard therapy for advanced head and neck cancer; however, due to CDDP-induced renal impairment, dose reduction or discontinuation is frequently required. Therefo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58e049e58bccfdb9dd993fe9a15c3fa8
https://doi.org/10.21873/invivo.12982
https://doi.org/10.21873/invivo.12982
Autor:
Yurie Katsube, Shin-ya Morita, Daiki Hira, Tetsuya Minegaki, Yoshito Ikeda, Tomohiro Terada, Masayuki Tsujimoto, Kohshi Nishiguchi, Hiroyoshi Koide
Publikováno v:
Drug Metabolism and Disposition. 49:289-297
Growing evidence suggests that certain glucuronides function as potent inhibitors of cytochrome P450 (CYP) 2C8. We previously reported the possibility of drug-drug interactions between candesartan cilexetil and paclitaxel. In this study, we evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e706ea4c4244c04abf5b7f4eccf8e7e
https://doi.org/10.1124/dmd.120.000126
https://doi.org/10.1124/dmd.120.000126
Autor:
Akihiro Kawauchi, Tetsuya Yoshida, Noriki Fujimoto, Takeshi Kato, Kazuya Teramura, Hiroyoshi Koide, Tomohiro Terada, Susumu Kageyama, Satoshi Noda
Publikováno v:
In Vivo
Background:We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab.
Case report:Case 1: A 50-year-old man with RCC received nivolum
Case report:Case 1: A 50-year-old man with RCC received nivolum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1c004e49d603d1383062c2d32f0104
https://doi.org/10.21873/invivo.12591
https://doi.org/10.21873/invivo.12591
Autor:
Kana Suenaga, Yasutaka Nakano, Satoshi Ueshima, Tomoyuki Okuda, Daiki Hira, Masafumi Yamaguchi, Eri Ishido, Hirokazu Okamoto, Hiroyoshi Koide, Shin-ya Morita, Mikio Kakumoto, Tomohiro Terada, Tomonobu Okano
Publikováno v:
Biologicalpharmaceutical bulletin. 44(6)
It is well known that correct use of inhalers plays a critical role in optimal inhalation therapy, but the impact of incorrect inhaler use on pulmonary drug delivery has not been quantitatively evaluated. The aim of this study was to investigate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78cb32a6ae4d42f028040df96cfa02c9
https://pubmed.ncbi.nlm.nih.gov/34078814
https://pubmed.ncbi.nlm.nih.gov/34078814
Autor:
Yurie, Katsube, Masayuki, Tsujimoto, Hiroyoshi, Koide, Daiki, Hira, Yoshito, Ikeda, Tetsuya, Minegaki, Shin-Ya, Morita, Tomohiro, Terada, Kohshi, Nishiguchi
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 49(4)
Growing evidence suggests that certain glucuronides function as potent inhibitors of CYP2C8. We previously reported the possibility of drug-drug interactions between candesartan cilexetil and paclitaxel. In this study, we evaluated the effects of can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bef55cb08dea2af786db40eb49bdbc31
https://pubmed.ncbi.nlm.nih.gov/33446524
https://pubmed.ncbi.nlm.nih.gov/33446524
Autor:
Megumi Ochiai, Kohshi Nishiguchi, Tomoyuki Yamakawa, Tetsuya Minegaki, Hiroyoshi Koide, Taku Furukubo, Satoshi Izumi, Kengo Kambara, Nao Torii, Masayuki Tsujimoto, Yurie Katsube, Ayako Hojyo, Daisuke Shima, Kaori Ogawa
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:783-789
Half-life of SN-38, an active metabolite of irinotecan, remarkably increases in patients with end-stage kidney disease (ESKD), even though SN-38 is excreted in bile. Uremic toxins (UTs), which accumulate in the serum of ESKD patients, were reported t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743bafef06e1423da2ac92196a9da999
https://doi.org/10.1007/s00280-017-3276-y
https://doi.org/10.1007/s00280-017-3276-y
Autor:
Tetsuya Minegaki, Daiki Hira, Yurie Katsube, Shin-ya Morita, Kohshi Nishiguchi, Takashi Uzu, Yoshito Ikeda, Hiroyoshi Koide, Masayuki Tsujimoto, Tomohiro Terada
Publikováno v:
Biological & Pharmaceutical Bulletin. 40:681-686
Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. Therefore, the present study, a retrospective inves
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c29a9d2257668923d7176a9390d7582d
https://doi.org/10.1248/bpb.b16-00972
https://doi.org/10.1248/bpb.b16-00972